Health Care and Biotech
Alcidion’s IT Targets Hospital Efficiency
Alcidion is an emerging operator in the field of hospital IT, with technology that can reduce deaths attributable to medical error. The stock price has doubled since it listed on ASX in February this year.
Dec 19 2016
Estia Health Beset By Uncertainty
Estia Health is beset by uncertainty surrounding the sustainability of earnings and this is not expected to moderate in the near term.
Dec 13 2016
Rebound For Sirtex
Michael Gable of Fairmont Equities suggests technically, Sirtex Medical should be set to recover.
Dec 13 2016
Sirtex Reaction Overdone
Increased competition has wedged dose sales for Sirtex Medical but brokers suspect the market’s reaction is overdone.
Dec 12 2016
Previous Stories
Pharmaxis On Investors’ Radar
Mar 11 2011
BA Merrill Lynch has initiated coverage on Pharmaxis with a Buy rating, adding to existing positive views from Credit Suisse and RBS Australia.
Mesoblast, The Next Cochlear?
Mar 07 2011
Southern Cross Equities has upgraded Mesoblast to Buy from Speculative Buy.
Significant Upside Potential In Alchemia
Feb 21 2011
Southern Cross Equities has initiated coverage on drug delivery group Alchemia with a Spec Buy rating, seeing significant potential upside.
Is CSL Expensive?
Feb 17 2011
CSL just beat consensus estimates for its interim result and retained full year earnings guidance, but with earnings headwinds appearing some in the market are questioning value.
Big Pharma Eyeing Oz Biotechs
Feb 09 2011
Big Pharma are picking up the pace of acquisitions in the biotech sector and Southern Cross equities suggests this offers some upside to the Australian plays.
Starpharma Offers Value In Oz Biotech Sector
Feb 03 2011
Starpharma is a leader in dendrimer technology and Southern Cross Equities views the stock as good value at current levels given the potential of the VivaGel product.
The Emerging Market Healthcare Trend That Nobody is Talking About
Jan 28 2011
Investment U’s Marc Lichtenfeld predicts biotech will make a come-back, on the back of strong trends in emerging markets.
Shifting Stockbroker Preferences
Jan 20 2011
Analysts and strategists at leading stockbrokerages continue making changes to their forecasts and preferences for the year ahead.
Schadenfreude For Cochlear
Nov 24 2010
With Advanced Bionics making a global recall of its cochlear implant product Cochlear is a likely beneficiary, to the extent two brokers have upgraded to Buy ratings on the stock.
Upgrades For Sonic
Nov 19 2010
Leading stockbrokers have seen an uptick in pathology volumes as enough to justify upgrades for the stock.
Analyse The Market From A Different Angle
Latest News
| 1 |
Weekly Update On LICs & LITs – 08-Jul-202511:00 AM - Weekly Reports |
| 2 |
Pinnacle’s Ready For New Highs10:30 AM - Technicals |
| 3 |
Uranium Week: U3O8 Spot Price Poised To Fall10:00 AM - Weekly Reports |
| 4 |
The Overnight Report: Tariff Truce’s Soft Extension8:42 AM - Daily Market Reports |
| 5 |
Today’s Financial Calendar – 08-07-20258:15 AM - Daily Market Reports |